Skip to main content

Table 3 Multivariate analysis of risk stratification of patients based on the CAFs FGF-2 and VEGF

From: Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial

Variable

PFS

OS

Risk group

Risk group

Low

Intermediate

High

Low

Intermediate

High

HR

(95 CI)

p

HR

(95 CI)

p

HR

(95 CI)

p

HR

(95 CI)

p

HR

(95 CI)

p

HR

(95 CI)

p

Sex

0.82

(0.59–1.18)

0.3698

0.74

(0.59–1.11)

0.9645

0.86

(0.62–1.08)

0.3438

0.80

(0.57–1.05)

0.3698

0.96

(0.68–1.33)

0.6905

0.86

(0.59–1.16)

0.5713

Age (< 65 years)

0.96

(0.69–1.35)

0.7647

0.87

(0.55–1.20)

0.2027

0.73

(0.59–0.98)

0.0455

0.97

(0.71–1.32)

0.7647

0.61

(0.44–0.85)

0.0047

0.60

(0.38–0.89)

0.0391

Isotype

0.91

(0.56–1.32)

0.2957

0.91

(0.64–1.31)

0.6951

0.96

(0.68–1.33)

0.6419

0.82

(0.51–1.21)

0.2957

0.83

(0.57–1.15)

0.3627

0.98

(0.81–1.22)

0.8179

D&S stage

0.84

(0.60–1.16)

0.3218

0.82

(0.57–1.22)

0.3505

0.64

(0.49–0.89)

0.0169

0.83

(0.59–1.11)

0.3218

0.98

(0.67–1.44)

0.7874

0.74

(0.59–1.12)

0.0593

ISS stage

0.94

(0.66–1.29)

0.8163

0.91

(0.55–1.24)

0.2107

0.84

(0.58–1.28)

0.0619

0.79

(0.61–1.07)

0.1087

0.97

(0.66–1.34)

0.5221

0.87

(0.62–1.27)

0.0665

Cytogenetic risk

0.93

(0.64–1.28)

0.6358

0.87

(0.56–1.22)

0.3451

0.91

(0.55–1.33)

0.6670

0.86

(0.71–1.32)

0.2399

0.89

(0.69–1.41)

0.6133

0.92

(0.71–1.37)

0.6112

Renal failure

0.94

(0.61–1.25)

0.5866

0.92

(0.59–1.44)

0.6957

0.87

(0.60–1.21)

0.2410

0.92

(0.66–1.41)

0.5866

0.94

(0.71–1.35)

0.6108

0.97

(0.74–1.25)

0.8902

Induction therapy

0.84

(0.61–1.28)

0.3520

0.93

(0.66–1.34)

0.6838

0.88

(0.58–1.18)

0.3356

0.84

(0.57–1.19)

0.3520

0.93

(0.70–1.32)

0.6075

0.89

(0.66–1.28)

0.6015

Best response to induction therapy (≥ VGPR)

0.76

(0.59–1.18)

0.0984

0.68

(0.48–0.96)

0.0342

0.71

(0.55–1.08)

0.0533

0.74

(0.59–1.09)

0.0984

0.95

(0.69–1.31)

0.5031

0.88

(0.61–1.29)

0.0583

Maintenance

0.70

(0.44–0.89)

0.0210

0.54

(0.38–0.80)

0.0008

0.71

(0.56–0.92)

0.0249

0.70

(0.48–0.88)

0.0210

0.74

(0.57–1.01)

0.0330

0.52

(0.36–0.75)

0.0003

  1. p values less than 0.05 was considered significant
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us